Company: BGLC
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001477932-25-003821
Chunk: 1

Company: BioNexus Gene Lab Corp
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 1
Chunk 1
---
 8   1,182,723   1,503,326 Other payables and accrued liabilities      287,189   284,108 Current portion of operating lease liabilities  5   52,173   50,816 Advance payment from customer      21,964   95,879 Amount owing to directors      16,314   17,174 Total current liabilities      1,560,363   1,951,303              NON-CURRENT LIABILITIES            Non-current portion of operating lease liabilities  5   147,940   159,741 Deferred tax liabilities  4   -   - Total non-current liabilities      147,940   159,741 TOTAL LIABILITIES     $1,708,303   2,111,044 

See accompanying notes to the consolidated financial statements.

 4Table of Contents

PART I — FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS (CONT’D)

BIONEXUS GENE LAB CORP. 

CONDENSED CONSOLIDATED BALANCE SHEETS 

AS OF MARCH 31, 2025 AND DECEMBER 31, 2024 

(Currency expressed in United States Dollars (“US$”))

     As of      March 31,  December 31,   Note  2025  2024     (Unaudited)  (Audited) STOCKHOLDERS’ EQUITY         As at March 31, 2025, common stock, no par value; 300,000,000 shares authorized and 17,967,663 shares outstanding, and preferred stock, no par value; 30,000,000 shares authorized and no shares outstanding. As at December 31, 2024, common stock, no par value; 300,000,000 shares authorized and 17,967,663 shares outstanding, and preferred stock, no par value 30,000,000 shares authorized and no shares outstanding (on a post-reverse stock split basis)*  12  $17,332,315  $17,332,315 Additional paid in capital      (5,011,891 )  (5,011,891 )Accumulated deficit      (4,065,947